Key points are not available for this paper at this time.
The occurrence of radiation necrosis to the extravasation of therapeutic radionuclide-yttrium-90-ibritumomab tiuxetan-is described, as well as the subsequent steps taken to both address the occurrence and to prevent the re-occurrence of such an adverse event. Published reports on the extravasation of diagnostic and therapeutic radionuclides are reviewed, as are prevention and treatment protocols.
Williams et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: